Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Novel Octahydropyrrolo[3,4-c]pyrroles Are Selective Orexin-2 Antagonists: SAR Leading to a Clinical Candidate
Michael A. Letavic, Pascal Bonaventure, Nicholas I. Carruthers, et al.
Journal of Medicinal Chemistry (2015) Vol. 58, Iss. 14, pp. 5620-5636
Closed Access | Times Cited: 38

Showing 1-25 of 38 citing articles:

Hypocretins (orexins): The ultimate translational neuropeptides
Laura H. Jacobson, Daniël Hoyer, Luı́s de Lecea
Journal of Internal Medicine (2022) Vol. 291, Iss. 5, pp. 533-556
Closed Access | Times Cited: 71
The Discovery of Suvorexant, the First Orexin Receptor Drug for Insomnia
Paul J. Coleman, Anthony L. Gotter, W. Joseph Herring, et al.
The Annual Review of Pharmacology and Toxicology (2016) Vol. 57, Iss. 1, pp. 509-533
Closed Access | Times Cited: 113
Orexin Receptor Antagonists: New Therapeutic Agents for the Treatment of Insomnia
Anthony J. Roecker, Christopher D. Cox, Paul J. Coleman
Journal of Medicinal Chemistry (2015) Vol. 59, Iss. 2, pp. 504-530
Closed Access | Times Cited: 107
Accurate Prediction of GPCR Ligand Binding Affinity with Free Energy Perturbation
Francesca Deflorian, Laura Pérez‐Benito, Eelke B. Lenselink, et al.
Journal of Chemical Information and Modeling (2020) Vol. 60, Iss. 11, pp. 5563-5579
Closed Access | Times Cited: 75
Imidazopyridine-based selective and multifunctional ligands of biological targets associated with psychiatric and neurodegenerative diseases
David Vanda, Paweł Zajdel, Miroslav Soural
European Journal of Medicinal Chemistry (2019) Vol. 181, pp. 111569-111569
Closed Access | Times Cited: 75
The roles of orexins in sleep/wake regulation
Michihiro Mieda
Neuroscience Research (2017) Vol. 118, pp. 56-65
Open Access | Times Cited: 73
Characterization of JNJ-42847922, a Selective Orexin-2 Receptor Antagonist, as a Clinical Candidate for the Treatment of Insomnia
Pascal Bonaventure, Jonathan Shelton, Sujin Yun, et al.
Journal of Pharmacology and Experimental Therapeutics (2015) Vol. 354, Iss. 3, pp. 471-482
Open Access | Times Cited: 71
Effects of Suvorexant, a Dual Orexin/Hypocretin Receptor Antagonist, on Impulsive Behavior Associated with Cocaine
Taylor A. Gentile, Steven J. Simmons, Mia N. Watson, et al.
Neuropsychopharmacology (2017) Vol. 43, Iss. 5, pp. 1001-1009
Open Access | Times Cited: 64
Geminal Diheteroatomic Motifs: Some Applications of Acetals, Ketals, and Their Sulfur and Nitrogen Homologues in Medicinal Chemistry and Drug Design
Yong‐Jin Wu, Nicholas A. Meanwell
Journal of Medicinal Chemistry (2021) Vol. 64, Iss. 14, pp. 9786-9874
Closed Access | Times Cited: 49
Hypocretin/Orexin Receptor Pharmacology and Sleep Phases
Yu Sun, Ryan K. Tisdale, Thomas S. Kilduff
Monographs in clinical neuroscience/Frontiers of neurology and neuroscience/Monographs in neural sciences (2021), pp. 22-37
Open Access | Times Cited: 42
Cu-Catalyzed Asymmetric 1,3-Dipolar Cycloaddition of N-2,2,2-Trifluoroethylisatin Ketimines Enables the Desymmetrization of N-Arylmaleimides: Access to Enantioenriched F3C-Containing Octahydropyrrolo[3,4-c]pyrroles
Zhen‐Hua Wang, Jihong Liu, Yanping Zhang, et al.
Organic Letters (2022) Vol. 24, Iss. 22, pp. 4052-4057
Closed Access | Times Cited: 33
Discovery of Nivasorexant (ACT-539313): The First Selective Orexin-1 Receptor Antagonist (SO1RA) Investigated in Clinical Trials
Jodi T. Williams, Martin H. Bolli, Christine Brotschi, et al.
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 4, pp. 2337-2348
Closed Access | Times Cited: 6
The selective orexin-2 receptor antagonist seltorexant improves sleep: An exploratory double-blind, placebo controlled, crossover study in antidepressant-treated major depressive disorder patients with persistent insomnia
Sander Brooks, Gabriël E. Jacobs, Peter de Boer, et al.
Journal of Psychopharmacology (2019) Vol. 33, Iss. 2, pp. 202-209
Closed Access | Times Cited: 52
Positional Analogue Scanning: An Effective Strategy for Multiparameter Optimization in Drug Design
Lewis D. Pennington, Brian Aquila, Younggi Choi, et al.
Journal of Medicinal Chemistry (2020) Vol. 63, Iss. 17, pp. 8956-8976
Closed Access | Times Cited: 43
Applications of Isosteres of Piperazine in the Design of Biologically Active Compounds: Part 2
Nicholas A. Meanwell, Olivier Loiseleur
Journal of Agricultural and Food Chemistry (2022) Vol. 70, Iss. 36, pp. 10972-11004
Closed Access | Times Cited: 27
Targeting orexin receptors: Recent advances in the development of subtype selective or dual ligands for the treatment of neuropsychiatric disorders
Alessandro Bonifazi, Fabio Del Bello, Gianfabio Giorgioni, et al.
Medicinal Research Reviews (2023) Vol. 43, Iss. 5, pp. 1607-1667
Closed Access | Times Cited: 13
The Quest for the Best Dual Orexin Receptor Antagonist (Daridorexant) for the Treatment of Insomnia Disorders
Christoph Boss, John Gatfield, Christine Brotschi, et al.
ChemMedChem (2020) Vol. 15, Iss. 23, pp. 2286-2305
Closed Access | Times Cited: 37
Pharmaco-EEG Studies in Animals: A History-Based Introduction to Contemporary Translational Applications
Wilhelmus Drinkenburg, A. Ahnaou, G.S.F. Ruigt
Neuropsychobiology (2015) Vol. 72, Iss. 3-4, pp. 139-150
Open Access | Times Cited: 35
Orexin OX2 Receptor Antagonists as Sleep Aids
Laura H. Jacobson, Sui Chen, Sanjida Mir, et al.
Current topics in behavioral neurosciences (2016), pp. 105-136
Open Access | Times Cited: 35
Saturated Heterocycles with Applications in Medicinal Chemistry
Charles M. Marson
Advances in heterocyclic chemistry (2016), pp. 13-33
Closed Access | Times Cited: 29
Characteristics of Seltorexant—Innovative Agent Targeting Orexin System for the Treatment of Depression and Anxiety
Wojciech Ziemichód, Antonina Kurowska, Karolina Grabowska, et al.
Molecules (2023) Vol. 28, Iss. 8, pp. 3575-3575
Open Access | Times Cited: 7
3-((Hetera)cyclobutyl)azetidines, “Stretched” Analogues of Piperidine, Piperazine, and Morpholine: Advanced Building Blocks for Drug Discovery
Illia O. Feskov, Anton V. Chernykh, Yuliya O. Kuchkovska, et al.
The Journal of Organic Chemistry (2018) Vol. 84, Iss. 3, pp. 1363-1371
Closed Access | Times Cited: 22
Synthesis and characterization of a new Positron emission tomography probe for orexin 2 receptors neuroimaging
Ping Bai, Yan Liu, Yulong Xu, et al.
Bioorganic Chemistry (2022) Vol. 123, pp. 105779-105779
Open Access | Times Cited: 10
Orexin research: patent news from 2016
Christoph Boss, Catherine Roch
Expert Opinion on Therapeutic Patents (2017) Vol. 27, Iss. 10, pp. 1123-1133
Closed Access | Times Cited: 17
Synthesis of 2‐Substituted 1,2,3‐Triazoles via an Intramolecular N–N Bond Formation
Cheng‐yi Chen, Xiaowei Lu, Mareike C. Holland, et al.
European Journal of Organic Chemistry (2019) Vol. 2020, Iss. 5, pp. 548-551
Closed Access | Times Cited: 17
Page 1 - Next Page

Scroll to top